Review paper

Immunogenicity of CAR T cells in cancer therapy

Volume: 18, Issue: 6, Pages: 379 - 393
Published: Feb 25, 2021
Abstract
Patient-derived T cells genetically reprogrammed to express CD19-specific chimeric antigen receptors (CARs) have shown remarkable clinical responses and are commercially available for the treatment of patients with certain advanced-stage B cell malignancies. Nonetheless, several trials have revealed pre-existing and/or treatment-induced immune responses to the mouse-derived single-chain variable fragments included in these constructs. These...
Paper Details
Title
Immunogenicity of CAR T cells in cancer therapy
Published Date
Feb 25, 2021
Volume
18
Issue
6
Pages
379 - 393
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.